Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $0.00 | $10.0M | $0.00 | $500K |
| Revenue growth | — | — | -100.0% | — |
| Operating income | -$54.4M | -$28.4M | -$47.4M | -$40.1M |
| Operating margin | — | -284.2% | — | -8021.4% |
| Net income | -$42.2M | -$29.5M | -$43.3M | -$41.9M |
| Net margin | — | -294.7% | — | -8375.6% |
| EPS (diluted) | -$0.07 | -$0.04 | -$0.06 | -$0.05 |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Operating cash flow | -$48.8M | -$21.1M | -$32.8M | -$31.0M |
| Capital expenditures | $13.0K | $0.00 | $0.00 | $20.0K |
| Free cash flow | -$48.8M | -$21.1M | -$32.8M | -$31.0M |
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Cash & equivalents | $68.2M | $57.4M | $69.8M | $41.0M |
| Total assets | $77.4M | $66.5M | $76.4M | $45.9M |
| Total liabilities | $26.0M | $16.0M | $15.4M | $5.00M |
| Shareholders' equity | $51.4M | $50.5M | $61.0M | $40.9M |
| Retained earnings | -$405M | -$420M | -$463M | -$501M |
| Shares (wtd avg diluted) | 603M | 659M | 740M | 797M |
Every figure is extracted from Mereo BioPharma Group plc’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.